ArticleVeterinary research2025
Getah virus nonstructural protein 2 suppresses interferon-beta production by interrupting interferon regulatory factor 3 activation.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Glycosylation of GETV E2 promotes pathogenesis in animal models.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Getah Virus in Review: An Emerging Zoonotic Arbovirus.Transboundary and emerging diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Getah virus (GETV), a neglected and re-emerging mosquito-borne alphavirus, has become more serious and poses a potential threat to animal safety and public health. The innate immune response is critical for host defence against viral infection, and the dysregulation of host innate immune responses likely aggravates GETV infection. In this study, we use unbiased screening to identify GETV proteins that antagonise type I interferon (IFN-I) response. We found that GETV Nsp2 could inhibit Sendai virus or poly(I:C)-induced IFN-β promoter activation, potently suppressing primary interferon production- a key component of the host's innate immunity antiviral response. Remarkably, Nsp2 showed efficient inhibition of the IRF3-responsive promoter, but not AP-1 or NF-κB. Further examination revealed that Nsp2 significantly suppressed luciferase activity when RIG-I-CARD, MDA5, MAVS, or IRF3 activated the IFN-β promoter. By contrast, IRF3/5D led to less suppression of luciferase expression, partially restoring luciferase activity, suggesting that Nsp2 interferes with the biological function of IRF3 as a crucial strategy in its antagonism of IFN-β production. Mechanistically, Nsp2 binds TBK1 to suppress IRF3 phosphorylation. Meanwhile, Nsp2 competitively inhibited the interaction of pIRF3 with KPNA3 and KPNA4, to inhibit IRF3 nuclear translocation. Overall, we demonstrated that GETV suppresses antiviral innate immunity by inhibiting the activation of IRF3, and Nsp2 plays a crucial role in this process. These findings reveal a novel strategy by which GETV evades the host innate immune response, providing new insights into the pathogenesis of GETV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.